DOKTOR FALK FARMA GMBKH, PREDSTAVITELSTVO
SOIBD Collagenous Colitis Maintenance Study
- Conditions
- Interventions
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 92
- Registration Number
- NCT01278082
- Locations
- 🇩🇪
Center of digestive diseases, Hamburg, Germany
🇸🇪University Hospital of Linköping, Linköping, Sweden
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 57
- Registration Number
- NCT01209208
- Locations
- 🇩🇪
Magen-Darm-Zentrum, IKE - Internistische Kooperation Eppendorf, Hamburg, Germany
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
- Conditions
- Interventions
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 835
- Registration Number
- NCT01208922
- Locations
- 🇮🇳
Site 122, Panaji, India
🇮🇳Site 102, Pondichéry, India
🇮🇳Site 103, Vijayawada, India
9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 471
- Registration Number
- NCT01086553
- Locations
- 🇩🇪
Med. Klinik I - Markus-Krankenhaus - Frankfurter Diakonie-Kliniken, Frankfurt, Germany
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 330
- Registration Number
- NCT01038739
- Locations
- 🇺🇸
United Medical Research, New Smyrna Beach, Florida, United States
Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine
- Conditions
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 78
- Registration Number
- NCT00946946
- Locations
- 🇩🇪
Robert-Bosch Krankenhaus, Innere Medizin I, Stuttgart, Germany
🇦🇹Universitaetsklinik für Innere Medizin III, Abteilung Gastroenterologie and Hepatologie, Vienna, Austria
Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)
- Conditions
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 186
- Registration Number
- NCT00887263
- Locations
- 🇩🇪
University of Regensburg, Regensburg, Germany
🇮🇱The Hebrew University-Hadassah School of Dental Medicine, Department of Oral Medicine, Jerusalem, Israel
Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 208
- Registration Number
- NCT00838214
- Locations
- 🇩🇪
Medical School Hannover, Hannover, Niedersachsen, Germany
Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2012-01-30
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 17
- Registration Number
- NCT00828230
- Locations
- 🇩🇪
Klinik für Radioonkologie und Strahlentherapie - Klinikum Braunschweig, Braunschweig, Germany
🇩🇪Strahlentherapie, St. Vincentius-Kliniken gAG, Karlsruhe, Germany
🇩🇪Strahlentherapie, Klinikum Mutterhaus der Borromäerinnen, Trier, Germany
Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)
- Conditions
- Interventions
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 62
- Registration Number
- NCT00746486
- Locations
- 🇩🇪
Universitätsklinikum Bonn, Bonn, NRW, Germany
🇫🇷Hôpital Saint-Antoine, Paris, France